Laying out AI in healthcare verticals: LuDe Medical and its equity-invested funds jointly inject capital into Zhejiang University’s AI healthcare newcomer Enmedi.

Caixin News (March 25) AI medical track begins shifting from large models to clinical practice, and the logic of capital allocation is undergoing a substantive turn—from competing in generalized capabilities to evaluating real clinical value and deployment efficiency. Precise breakthroughs in vertical scenarios have become the investment mainline for the next round.

On March 24, 2026, an AI medical company incubated by the Huzhou Research Institute of Zhejiang University—Huzhou Enmeidi Artificial Intelligence Technology Co., Ltd. (abbreviated as “Enmeidi”)—announced that it has completed tens of millions of RMB in angel round financing. This round was co-led by Lude Medical (920278.BJ) and its affiliated Chuzhou Shicheng Lude Venture Capital Fund. The funds will be mainly used for R&D iteration and industrialization advancement of a remote AI-assisted heart and lung sound screening and quality control system, further extending related services into primary healthcare and home health management scenarios.

This deal shows a typical coordination feature of “industrial capital + application scenarios.” As a medical device company that has long been deeply focused on stethoscopes and respiratory system monitoring, Lude Medical has a mature manufacturing system and a global channel network. Its entry not only provides financial support, but also forms coordinated backing in product transformation, registration and compliance, and commercial promotion. This kind of investment approach that deeply binds resources across the industrial chain is increasingly seen as a key path for AI medical companies to cross the “final mile” of commercialization.

Lude Medical’s president, Xiang Youliang, said, “Lude Medical has long been deeply focused on cardiovascular monitoring and respiratory therapy. Our vision for building full-scenario heart-lung-respiratory health management together with Enmeidi is highly aligned. We will fully leverage our mature production and manufacturing capabilities, comprehensive global channel network, and compliance system advantages, accelerate the industrialized implementation and promotion of Enmeidi’s AI-assisted auscultation technology, and help innovative outcomes reach clinical and home settings. At the same time, Enmeidi’s leading AI technology and accumulation of clinical data will also deeply empower Lude Medical’s product intelligent upgrades and enrich its health management product matrix.”

According to public information, Enmeidi was founded in 2025, focusing on the high-frequency, rigid-demand scenario of early screening for heart and lung diseases. Its core product is an AI-assisted auscultation system. The system is trained on multimodal heart and lung sound data models and can identify multiple diseases, including structural heart disease, congenital heart disease, and COPD. Among them, the sensitivity for detecting pediatric congenital heart disease is 94%, specificity is 89%, and the identification accuracy for structural heart disease reaches 95%.

Enmeidi’s moat mainly lies in its three-in-one capabilities of “data + compliance + hardware.” On the one hand, its algorithm models are trained on more than 100,000 high-quality clinical heart and lung sound samples, forming a data advantage that can be continuously iterated. On the other hand, the electronic stethoscope hardware on which the system relies has obtained triple medical device certifications from the U.S. FDA, the EU CE, and China’s NMPA, laying a compliance foundation for subsequent large-scale promotion and potential overseas expansion.

It is reported that the system has been deployed and in operation for less than half a year, and has already been rolled out in more than 30 medical institutions nationwide. It has cumulatively served tens of thousands of patients, covering a variety of scenarios such as health checkups, valve disease screening, and community chronic disease management. Compared with asset-heavy pathways like imaging AI, auscultation-type AI has the advantages of low equipment costs and flexible deployment, making it more aligned with the actual needs of primary healthcare systems and easier to scale and replicate.

According to its plan, Enmeidi will further focus on building a national heart and lung sound database, and promote the rollout of a heart and lung sound interpretation and quality control center system, continuously strengthening algorithm capabilities and the density of the service network to build a closed-loop capability from data acquisition to clinical services.

In recent times, the AI medical track has been recovering. In early February, the AI drug unicorn “Deeply Zhiyou” announced the completion of a new round of financing totaling $60 million, led by CTC Capital, an investor with deep industrial background. Its core logic is to reshape the drug R&D infrastructure through a proprietary multi-agent ecosystem. Meanwhile, in the medical device and health management track, the “Maxwell” focusing on AI + 3D printing and “Yiyuan Longevity,” which has been deeply developing AI longevity medicine, also completed financing in January.

From this, it appears that industrial capital (CVC), represented by pharmaceutical industry leaders and device giants, is moving from behind the scenes to the front stage of AI medical care. From AstraZeneca’s China Jinchang Medical Industry Fund’s frequent bets on AI early screening, to last year’s massive financing as iFlytek (Intelligent Vision) built a digital intelligence foundation, and then to Lude Medical’s entry this time, industrial capital is seizing core algorithm and application entry points through equity ties.

Huge amounts of information and precise interpretation—right in the Sina Finance app